Assays and methods for verifying the validity of a urine sample submitted for Drugs of Abuse (DOA) testing. Embodiments include a SUD Diagnostic Panel that includes six assays: specific gravity index assay, long-duration counterfeit urine assay, short-duration counterfeit urine assay, oxidant history assay, pH assay, and creatinine assay. The SUD Diagnostic Panel detects twelve principle classes of adulteration. Detection of adulteration of one or more urine samples from a patient indicates an attempt to subvert test results and provides an objective indication in one instance and an object diagnosis in another instance of SUD.

Methods and apparatuses for rapid detection and quantification of analytes are disclosed. The analytes may be opioids such as fentanyl. The method includes the use of an internal standard. The internal standard is introduced into the unknown sample. The method may involve a separation step prior to an electrochemical detection step. In some embodiments, the separation step is omitted. The analyte may be selectively adsorbed onto a surface of an electrode by maintaining a potential on the electrode during which a solution containing the dissolved analyte flows through the electrode. Performing electroanalysis on the analyte-adsorbed electrode detects and quantifies only the adsorbed analyte. In some embodiments, the internal standard is methyl vanillate.

The invention generally relates to a sample dispenser including an internal standard and methods of use thereof.

The application relates to a chemical monitoring system comprising a skin patch for detecting an analyte in perspiration and a processor adapted to receive parameter data and to return an output indicative of a presence of an analyte in a subject's body based on the parameter data. The skin patch (100) includes a first layer (105) permeable to perspiration; a second layer (110) coupled to the first layer, the second layer being adapted to receive the perspiration; wherein a property of the second layer changes upon receiving the analyte; an electrical detector coupled to the second layer, adapted to detect parameter data indicative of the property of the second layer; and a flexible electronic circuit (140) coupled to the second layer, comprising a readout circuit for reading parameter data from the electronic detector and a transmitter adapted to transmit the parameter data to a processor.

The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

The invention generally relates to a sample dispenser including an internal standard and methods of use thereof.

One aspect of the invention provides a method of determining metal ion levels in the patents due to corrosion and wear processes of the metallic implant in a human or veterinary patient. One embodiment provides a cost effective and patient driven early diagnostic method which has a potential application in orthopedics and dentistry. In one embodiment, the method includes the use of an electrochemical biosensor to detect metal ions or particles in a sample taken from a patient having a metallic implant.

A method for diagnosing COVID-19 infection. The method includes drawing a blood sample from a person suspected to be infected with COVID-19 virus, separating a blood serum sample from the blood sample by centrifuging the blood sample, recording an electrochemical impedance spectroscopy (EIS) associated with the blood serum sample, calculating a charge transfer resistance (R.sub.CT) of the recorded EIS by measuring a diameter of a semicircular curved part of the recorded EIS, and detecting a COVID-19 infection of the person based on the calculated R.sub.CT if the calculated R.sub.CT is equal to or more than a threshold value.

A method and a system for evaluating a drug concentration in body fluid samples, wherein the body fluid samples are blood, plasma or serum, the method including the steps of: preparing at least one body fluid sample including a solved target drug by removing unsolved components from the body fluid sample; performing absorption spectrophotometric analyzes on the at least one body fluid sample; and evaluating a drug concentration in the at least one body fluid sample based on the spectrophotometric analyzes.

A method for diagnosing COVID-19 infection of a person. The method includes acquiring a sputum sample of the person, measuring a level of reactive oxygen species (ROS) in the sputum sample, and detecting a COVID-19 infection status of the person based on the measured level of ROS. Measuring the level of ROS in the sputum sample includes recording a cyclic voltammetry (CV) pattern from the sputum sample and measuring a current peak of the recorded CV pattern. Detecting the COVID-19 infection status of the person based on the measured level of ROS includes detecting the person is infected with COVID-19 if the measured current peak is in a first range of current peaks and detecting the person is not infected with COVID-19 if the measured current peak is in a second range of current peaks.